Global DNA Vaccine Pipeline Analysis

Publish Date:- Oct-2013       No Of Pages (130)

Electronic Access - Single User License $1500 Buy Now
CD-ROM Mail Delivery $1800Buy Now
Hard Copy Mail Delivery $2400 Buy Now
Electronic Access - Multi-User License $3000 Buy Now


The global market for DNA vaccines is currently recording significant growth rates owing to the lesser side effects, ease of development, lesser cost and continued development in biotechnology arena. At present, not even a single DNA vaccine has been approved for human beings. However, around 100 products are under clinical trial for treating diseases like HIV infection, cancer and other infectious diseases. With regards to animal health, there are three DNA vaccines which have been approved. The first vaccine against West Nile Virus to be used in horses was approved in 2005.

Global DNA Vaccine Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various DNA Vaccines being developed for the treatment of multiple diseases. Research report covers all the DNA Vaccines being developed in various development phases. Each DNA Vaccine profiles include detailed information like: Originator, Owner, Collaborator, Technology Provider, Licensee, Development Phase, Development Indications, Mechanism of Action, Country of Development and detailed analysis on the development process.

This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the DNA vaccine market based upon development process. Following parameters for each DNA Vaccine profile in development phase are covered in “Global DNA Vaccine Pipeline Analysis” research report:

• Drug Profile Overview

• Alternate Names for Drug

• Active Indication

• Phase of Development

• Mechanism of Action

• Brand Name

• Patent Information

• Orphan Designation by Indication, Country & Organisation

• Country for Clinical Trial

• Owner / Originator/ Licensee/Collaborator

• Administrative Route

• Drug Class

• ATC Codes



Breakup of DNA Vaccine Pipeline by Clinical Phase:

• Research: 2

• Preclinical: 25

• Phase-I: 24

• Phase-I/II: 6

• Phase-II: 9

• Phase-II/III: 1

• Phase-III: 2

• Discontinued: 31


The global market for DNA vaccines is currently recording significant growth rates owing to the lesser side effects, ease of development, lesser cost and continued development in biotechnology arena. At present, not even a single DNA vaccine has been approved for human beings. However, around 100 products are under clinical trial for treating diseases like HIV infection, cancer and other infectious diseases. With regards to animal health, there are three DNA vaccines which have been approved. The first vaccine against West Nile Virus to be used in horses was approved in 2005.

Global DNA Vaccine Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various DNA Vaccines being developed for the treatment of multiple diseases. Research report covers all the DNA Vaccines being developed in various development phases. Each DNA Vaccine profiles include detailed information like: Originator, Owner, Collaborator, Technology Provider, Licensee, Development Phase, Development Indications, Mechanism of Action, Country of Development and detailed analysis on the development process.

This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the DNA vaccine market based upon development process. Following parameters for each DNA Vaccine profile in development phase are covered in “Global DNA Vaccine Pipeline Analysis” research report:

• Drug Profile Overview

• Alternate Names for Drug

• Active Indication

• Phase of Development

• Mechanism of Action

• Brand Name

• Patent Information

• Orphan Designation by Indication, Country & Organisation

• Country for Clinical Trial

• Owner / Originator/ Licensee/Collaborator

• Administrative Route

• Drug Class

• ATC Codes



Breakup of DNA Vaccine Pipeline by Clinical Phase:

• Research: 2

• Preclinical: 25

• Phase-I: 24

• Phase-I/II: 6

• Phase-II: 9

• Phase-II/III: 1

• Phase-III: 2

• Discontinued: 31

1. Global DNA Vaccine Market Overview

  1.1 Current Market Scenario

  1.2 Key Drivers for Adopting DNA Vaccine

  1.3 Future Opportunity



2. DNA Vaccine Development Phase: Research

  2.1 Overview

  2.2 DNA Vaccine Profile in Development Phase



3. DNA Vaccine Development Phase: Preclinical

  3.1 Overview

  3.2 DNA Vaccine Profile in Development Phase



4. DNA Vaccine Development Phase: Phase-I

  4.1 Overview

  4.2 DNA Vaccine Profile in Development Phase



5. DNA Vaccine Development Phase: Phase- I/II

  5.1 Overview

  5.2 DNA Vaccine Profile in Development Phase



6. DNA Vaccine Development Phase: Phase-II

  6.1 Overview

  6.2 DNA Vaccine Profile in Development Phase



7. DNA Vaccine Development Phase: Phase-II/III

  7.1 Overview

  7.2 DNA Vaccine Profile in Development Phase



8. DNA Vaccine Development Phase: Phase-III

  8.1 Overview

  8.2 DNA Vaccine Profile in Development Phase



9. DNA Vaccine Discontinued Profiles

  9.1 Overview

  9.2 DNA Vaccine Profile in Development Phase


Each Drug Profile has Tables Representing Following Information:

• Alternate Names

• Originator & Owner

• Collaborator

• Technology Provider

• Licensee

• Highest Development Phase

• Indications

• Class

• Mechanism of Action

• ATC code

• Designated Brand Name & Orphan Designation